Trust Signals
- All efficacy claims are evidence-graded. Speculative claims are labeled as such.
- No paid supplement or clinic partnerships influence this content.
-
Enclomiphene is an estrogen receptor antagonist that raises LH and FSH to stimulate testicular testosterone production. Sermorelin is a synthetic GHRH analogue that stimulates the pituitary to release growth hormone. They target entirely different axes and are not interchangeable.
Can enclomiphene and sermorelin be used together?
They act on separate axes, so there is no direct pharmacological conflict. Some clinicians prescribe both simultaneously when a patient has both secondary hypogonadism and documented GH insufficiency, but combined use lacks dedicated safety or efficacy trial data.Does enclomiphene actually raise testosterone?
Yes. Phase II trials by Repros Therapeutics showed enclomiphene raised serum testosterone to normal range in men with secondary hypogonadism while preserving sperm counts. The FDA declined approval in 2016 citing long-term safety data gaps, not lack of efficacy signal.Does sermorelin actually raise IGF-1 or growth hormone?
Yes, when administered by injection. Small controlled studies show sermorelin raises GH pulse amplitude and serum IGF-1, particularly in GH-deficient adults. Effect size in eugonadal, non-deficient adults is smaller and less consistent. Oral or sublingual bioavailability is negligible without a demonstrated peptide carrier.What is the main regulatory status of each compound?
Enclomiphene is an unapproved drug in the US; it can be prescribed off-label or dispensed by a licensed 503B compounding pharmacy. Sermorelin (as acetate) had FDA approval as Geref but was withdrawn from commercial sale; it is now available only through compounding pharmacies in the US.How is enclomiphene dosed?
Clinical trials used oral doses of 12.5 mg to 25 mg daily. Most compounding protocols mirror this range. Doses above 25 mg daily are not supported by published efficacy data and increase estrogenic side-effect risk.How is sermorelin dosed and administered?
Standard clinical dosing is 0.2 mcg to 0.3 mcg per kg of body weight administered subcutaneously at bedtime, aligning with the natural GH pulse. Some protocols use 100 mcg to 300 mcg flat dosing nightly. Reconstitute lyophilized powder with bacteriostatic water; once reconstituted, store at 2 to 8 degrees Celsius and use within 30 days.What are the main side effects of each?
Enclomiphene: visual disturbances, mood changes, and estrogenic effects if conversion is high. Sermorelin: injection site reactions, flushing, and headache in a minority of users; water retention at higher doses. Neither has an established long-term safety database in healthy adults.Which compound has stronger clinical evidence?
Enclomiphene has Phase II human RCT data in a defined patient population (secondary hypogonadism). Sermorelin has smaller controlled trials in GH-deficient adults. Neither has Phase III approval for the off-label wellness indications most users are seeking.Who is a better candidate for enclomiphene vs sermorelin?
Enclomiphene suits men with documented secondary hypogonadism who want to preserve fertility. Sermorelin suits adults with documented low IGF-1 or GH insufficiency under medical supervision.What does a degraded sermorelin vial look like?
A degraded sermorelin solution may appear cloudy or contain visible particulates; a fresh solution is clear and colorless. Cloudiness, color change, or precipitate are reasons to discard. Lyophilized powder that has yellowed or clumped before reconstitution also indicates degradation.Is enclomiphene better than clomiphene for men?
Enclomiphene is the trans-isomer of clomiphene and appears to have a cleaner receptor profile in men. Clomiphene contains both zuclomiphene (estrogenic) and enclomiphene (anti-estrogenic) isomers. In trials, enclomiphene alone produced similar testosterone elevation with potentially fewer estrogenic side effects, though head-to-head superiority in large trials has not been definitively established.Sources
- Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. "The treatment of hypogonadism in men of reproductive age." Fertility and Sterility. 2013;99(3):718-724. (Enclomiphene Phase II trial data discussed within broader review context.)
- Wiehle R, Cunningham GR, Pitteloud N, et al. "Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study." BJU International. 2013;112(8):1188-1200.
- Walker RF, Codd EE, Barone FC, et al. "Oral administration of growth hormone (GH) releasing hexapeptide stimulates GH secretion in normal men." Journal of Clinical Endocrinology and Metabolism. 1990 (reference to early GHRH peptide work; sermorelin Walker-era studies).
- Sigalos JT, Zito PM. "Enclomiphene." StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.
- Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999;12(2):139-157.
- U.S. FDA. Complete Response Letter for Androxal (enclomiphene citrate). 2016. Available via FDA drug database records.
- U.S. Pharmacopeia. General Chapter 1 (Injections and Implanted Drug Products). USP-NF.
- Bhasin S, Cunningham GR, Hayes FJ, et al. "Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology and Metabolism. 2010;95(6):2536-2559.
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology and Metabolism. 2011;96(6):1587-1609.
Footer Disclaimers
Platform: This content is published by FormBlends for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting any medication or peptide protocol.
From the FormBlends catalog
Sermorelin
Bioidentical GHRH analog for natural growth hormone pulsatility · From $175/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sermorelin →Research Compound or Compounded Medication: Enclomiphene and sermorelin are not FDA-approved for the indications discussed in this article. Both are available in the United States only through licensed compounding pharmacies. Compounded products are not FDA-approved and may vary in purity, potency, and sterility compared to approved drug products.
Results: Individual results vary. Clinical outcomes described in cited studies were observed in specific patient populations under controlled conditions and may not apply to healthy individuals or those using these compounds outside of a supervised clinical setting.
Trademark: Geref is a registered trademark of Serono. Androxal is a registered trademark of Repros Therapeutics. FormBlends has no affiliation with these companies. All trademarks referenced are the property of their respective owners and are used here for identification and comparative purposes only.
Related peptide guides
Ready when you are
Sermorelin
Bioidentical GHRH analog for natural growth hormone pulsatility · From $175/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sermorelin →